CN1697663A - 抗肿瘤剂及其制备方法 - Google Patents

抗肿瘤剂及其制备方法 Download PDF

Info

Publication number
CN1697663A
CN1697663A CNA2004800006708A CN200480000670A CN1697663A CN 1697663 A CN1697663 A CN 1697663A CN A2004800006708 A CNA2004800006708 A CN A2004800006708A CN 200480000670 A CN200480000670 A CN 200480000670A CN 1697663 A CN1697663 A CN 1697663A
Authority
CN
China
Prior art keywords
sma
antitumor agent
pirarubicin
complex
micelle
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2004800006708A
Other languages
English (en)
Chinese (zh)
Inventor
前田浩
卡雷德具礼志
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CN1697663A publication Critical patent/CN1697663A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6907—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a microemulsion, nanoemulsion or micelle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Dispersion Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nanotechnology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CNA2004800006708A 2003-05-26 2004-02-02 抗肿瘤剂及其制备方法 Pending CN1697663A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP147852/2003 2003-05-26
JP2003147852 2003-05-26

Publications (1)

Publication Number Publication Date
CN1697663A true CN1697663A (zh) 2005-11-16

Family

ID=33475378

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2004800006708A Pending CN1697663A (zh) 2003-05-26 2004-02-02 抗肿瘤剂及其制备方法

Country Status (11)

Country Link
US (1) US7682630B2 (enExample)
EP (1) EP1627645B1 (enExample)
JP (1) JP4669393B2 (enExample)
CN (1) CN1697663A (enExample)
AU (1) AU2004241830B9 (enExample)
CA (1) CA2489259C (enExample)
ES (1) ES2642179T3 (enExample)
HU (1) HUE035003T2 (enExample)
PT (1) PT1627645T (enExample)
TW (1) TW200505414A (enExample)
WO (1) WO2004103409A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2605205C (en) * 2005-04-18 2011-11-01 Hiroshi Maeda Polymeric pharmaceutical agent for treatment of cancer and method for production of the same
DE602006017567D1 (de) * 2005-09-12 2010-11-25 Bendale N Neues bioplatin, herstellungsverfahren, verfahren zur verabreichung einer antitumoralen behandlung
FR2922452B1 (fr) * 2007-10-19 2010-01-22 Coatex Sas Formulations de composes organoplatiniques en presence de polymeres associatifs, produits obtenus et leurs utilisations
JP2010013411A (ja) * 2008-07-05 2010-01-21 Hiroshi Maeda 抗炎症剤
CA2977873C (en) 2011-09-05 2020-05-12 Hiroshi Maeda Polymer-type fluorescent molecule probe
JP6083738B2 (ja) * 2013-03-06 2017-02-22 公立大学法人大阪市立大学 ホウ素中性子捕捉療法用組成物およびその製造方法
US20160303242A1 (en) 2013-12-09 2016-10-20 Durect Corporation Pharmaceutically Active Agent Complexes, Polymer Complexes, and Compositions and Methods Involving the Same

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0087957B1 (en) * 1982-02-27 1986-11-26 Kuraray Co., Ltd. Neocarzinostatin complexes, a method for producing the same, and an antitumor agent containing said complexes as an active component
JPS58149903A (ja) * 1982-02-27 1983-09-06 Kuraray Co Ltd ネオカルチノスタチン複合体の製造法
JPS6075499A (ja) 1983-08-08 1985-04-27 Kuraray Co Ltd ネオカルチノスタチン誘導体及びその製造法
JP2556865B2 (ja) * 1986-09-19 1996-11-27 山之内製薬株式会社 ネオカルチノスタチン誘導体の非注射投与用組成物
US5281710A (en) * 1990-08-01 1994-01-25 The Scripps Research Institute Dynemicin analogs: synthesis, methods of preparation and use
ATE196844T1 (de) * 1996-05-22 2000-10-15 Protarga Inc Zusammensetzungen die konjugate von cis- docosahexaenoic-säure und taxotere enthalten
GB0001481D0 (en) * 2000-01-21 2000-03-15 Theryte Ltd System for delivering a medicament
KR100446101B1 (ko) * 2000-12-07 2004-08-30 주식회사 삼양사 수난용성 약물의 서방성 제형 조성물

Also Published As

Publication number Publication date
AU2004241830B2 (en) 2010-02-25
AU2004241830B9 (en) 2010-04-22
EP1627645A4 (en) 2008-12-24
HUE035003T2 (en) 2018-05-02
US20050208136A1 (en) 2005-09-22
TWI332834B (enExample) 2010-11-11
AU2004241830A1 (en) 2004-12-02
CA2489259C (en) 2011-08-30
EP1627645A1 (en) 2006-02-22
CA2489259A1 (en) 2004-12-02
US7682630B2 (en) 2010-03-23
EP1627645B1 (en) 2017-08-23
WO2004103409A1 (ja) 2004-12-02
JPWO2004103409A1 (ja) 2006-07-20
TW200505414A (en) 2005-02-16
JP4669393B2 (ja) 2011-04-13
ES2642179T3 (es) 2017-11-15
PT1627645T (pt) 2017-11-23

Similar Documents

Publication Publication Date Title
CN1214818C (zh) 共聚物胶束药物组合物及其制备方法
CN110101684A (zh) 一种生物正交靶向的细胞膜仿生纳米颗粒及其制备方法和用途
CN1469735A (zh) 米托蒽醌的脂质体制剂
JP5294858B2 (ja) 生理活性ポリペプチドまたはタンパク質内包高分子ポリマーミセルおよびその製造方法
TW201008582A (en) Docetaxel polymer derivative, method for producing same and use of same
Li et al. Photodynamic therapy-mediated remote control of chemotherapy toward synergistic anticancer treatment
CN107744593B (zh) 一种叶酸靶向抗肿瘤药物缓释载体及其制备方法
CN105377302B (zh) 聚合物胶束医药组合物
JPWO2012067138A1 (ja) 新規なシチジン系代謝拮抗剤の高分子誘導体
US20220162382A1 (en) Production of nanoparticles and microparticles
CN103881088A (zh) 一种响应性聚合物胶束载药体系及其制备方法
CN1697663A (zh) 抗肿瘤剂及其制备方法
EP4355367A1 (en) Self-assembling nanoparticles based on amphiphilic peptides for drug delivery applications
CN104367556B (zh) 一种能提供一氧化氮的透明质酸硝酸酯去氧胆酸聚合物胶束的制备方法及其应用
CN108126210B (zh) 一种单靶向还原响应囊泡纳米药物在制备脑肿瘤治疗药物中的应用
US20180339053A1 (en) Use of 1,2-dicarboxylic acid monoamide polymer as synergist for chemotherapy
WO2018038155A1 (ja) ミセル及びその使用
WO2006112362A1 (ja) 高分子型癌治療用医薬の製造方法
CN112979881B (zh) 促抗癌药摄入的大分子、组合物及其制备抗癌药物的用途
Lee et al. Polyethylenimine-g-poly (lactic-co-glycolic acid) as non-toxic micelle-type carrier for gene delivery
CN102462846A (zh) 一种氯代毒素修饰的脑胶质瘤靶向基因递释复合物及其制备方法
CN119055785B (zh) 一种药物聚合物、肿瘤靶向纳米聚合药物及其制备方法和应用
CN110974962A (zh) 肿瘤免疫凝胶制剂的合成方法
CN119679750B (zh) 一种仿生的癌细胞膜工程化顺铂的纳米药物及其制备方法和应用
TW201304804A (zh) 核酸傳遞化合物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Open date: 20051116